BIO3 — Biotest AG Cashflow Statement
0.000.00%
Last trade - 00:00HealthcareConservativeMid CapNeutral
- €1.33bn
- €1.80bn
- €515.60m
- 44
- 19
- 61
- 33
Annual cashflow statement for Biotest AG, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2017 December 31st | 2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -26 | -6 | -1.3 | -30 | -62.7 |
| Depreciation | |||||
| Non-Cash Items | 54.1 | 16.5 | 1.1 | 25 | 17.5 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -16.1 | -85.2 | -65.1 | -41.3 | 48 |
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 34.3 | -50 | -33.6 | -16.7 | 33.9 |
| Capital Expenditures | -107 | -54.6 | -34.1 | -27 | -18.2 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -41.5 | 255 | 26.1 | 12.4 | -5.2 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -148 | 201 | -8 | -14.6 | -23.4 |
| Financing Cash Flow Items | -1.1 | -15.2 | 2.7 | 0.1 | 3.6 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 55.2 | -111 | 40.5 | 42 | 22.6 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -58.7 | 39.6 | -1.1 | 10.5 | 33.1 |